Experimental Drug DNL343 Fails to Slow ALS Progression in Randomized Trial

A randomized clinical trial published in JAMA Network Open has found that DNL343, an experimental drug designed to activate a key cellular stress-response pathway, did not slow disease progression in people with amyotrophic lateral sclerosis. The result is a sobering setback for a therapeutic strategy that had generated considerable enthusiasm in the ALS research community, because it targets a biological mechanism with strong genetic and mechanistic ties to neurodegeneration. Despite encouraging evidence that the drug reached its intended molecular target at the doses tested, the trial found no signal that this engagement translated into a meaningful clinical benefit for patients.

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease characterized by the loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. Most patients survive only two to five years after symptom onset, and the therapeutic landscape remains starkly limited. Only a small number of approved treatments modestly extend survival or slow functional decline, and none stop the disease. This unmet need has driven intense interest in biological pathways that might be exploited to protect vulnerable motor neurons, and few have attracted as much attention as the integrated stress response.

The integrated stress response is a fundamental cellular signaling network that governs how cells react to a wide range of stressors, including nutrient deprivation, viral infection, oxidative damage, and the accumulation of misfolded proteins. At the center of this pathway sits a molecular complex involving eukaryotic initiation factor 2, or eIF2, and its regulatory subunit eIF2B. When cells perceive stress, phosphorylation of eIF2 suppresses general protein synthesis while selectively boosting the production of stress-adaptive proteins. This is a protective maneuver in the short term, but in chronic diseases, sustained activation of the stress response can become maladaptive, starving neurons of the proteins they need to maintain synapses and survive over decades.

The rationale for targeting this pathway in ALS is rooted in human genetics. Mutations in genes encoding subunits of eIF2B cause vanishing white matter disease, a devastating leukodystrophy, and have also been linked to ALS-like syndromes. Beyond genetics, protein aggregation is a hallmark of ALS pathology: misfolded forms of proteins such as TDP-43 accumulate in the neurons and glia of nearly all patients with the disease. Because the integrated stress response is activated by proteotoxic stress, researchers hypothesized that modulating it could relieve a chronic burden on motor neurons and slow their degeneration. Preclinical studies in cell and animal models supported this idea, showing that enhancing eIF2B activity could restore protein synthesis and improve cellular resilience.

DNL343, developed by Denali Therapeutics, was designed as a small-molecule activator of eIF2B. The drug works upstream of the pathological bottleneck, aiming to increase the activity of the eIF2B complex and thereby restore more normal rates of protein synthesis even when the integrated stress response is chronically engaged. A notable feature of the development program was its emphasis on pharmacology: in a prior phase 1b clinical trial in ALS, DNL343 demonstrated proof of mechanism, showing that it could engage its target in the central nervous system, and the data supported selection of an optimal dose for further testing. Biomarker evidence suggested the compound was doing what it was designed to do in patients’ bodies.

That foundation made the new randomized trial, conducted by a team led by corresponding author Sabrina Paganoni of the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital, a critical test of the hypothesis. The study evaluated a daily dose of 200 milligrams of DNL343 against control in people with ALS, with disease progression as the central question. Randomized clinical trials of this kind are the gold standard for determining whether a biologically plausible intervention actually changes the trajectory of a disease, and ALS trials typically measure outcomes such as the rate of decline on the ALS Functional Rating Scale, a validated measure of motor function used to track disease course.

The result was unambiguous in its disappointment: 200 milligrams per day of DNL343 did not show evidence of slowing disease progression. In other words, even though the drug had previously demonstrated that it could activate the eIF2 pathway at appropriate doses, that molecular engagement did not produce a detectable clinical benefit in this trial. This dissociation between proof of mechanism and proof of efficacy is one of the most instructive and frustrating patterns in neurodegenerative disease research, and it raises difficult questions about where the therapeutic hypothesis breaks down.

Several non-exclusive explanations deserve consideration. One possibility is that by the time patients enroll in ALS trials, the degenerative process has advanced beyond the point where restoring protein synthesis can rescue motor neurons, a timing problem that plagues many neurodegeneration therapies. Another is that the integrated stress response, while clearly implicated in ALS biology, may be only one node in a much larger network of dysfunction involving mitochondrial failure, impaired axonal transport, neuroinflammation, RNA dysregulation, and glial toxicity; correcting a single node may be insufficient to alter the course of a multifactorial disease. It is also possible that the degree of eIF2B activation achievable safely in humans, even at the optimized dose, falls short of what preclinical models suggested was needed, or that the relevant biology differs between model systems and human motor neurons in ways that animal studies could not fully capture.

The authors of the study framed the outcome as highlighting the need for alternative therapeutic approaches, a conclusion that carries weight precisely because the trial was well designed and built on rigorous dose-selection and mechanism-confirmation work. Negative trials that test a strong hypothesis cleanly are scientifically valuable: they redirect the field away from strategies that do not work in humans and toward approaches that might. For DNL343 specifically, the result does not necessarily invalidate eIF2B biology as a therapeutic target in all contexts, but it does suggest that simply activating the pathway with a daily oral dose is not sufficient to modify ALS progression in the population studied.

For patients and families, the news is a reminder of how difficult ALS drug development remains. The disease has one of the highest failure rates of any therapeutic area, with numerous agents that looked promising in laboratory and early clinical studies failing to change disease course in definitive trials. Each well-conducted negative study, however painful, refines the map of what is and is not likely to help. The ALS research community continues to pursue a broad portfolio of strategies, from gene-targeted therapies for specific mutations to antisense oligonucleotides, immunomodulatory approaches, and combination regimens, in the hope that a deeper understanding of disease mechanisms will eventually yield treatments capable of meaningfully slowing or halting this relentless disease. The full study, including the complete author list, disclosures, and funding information, is available in JAMA Network Open.

Subject of Research: A randomized clinical trial testing the eIF2B activator DNL343 for slowing ALS disease progression

Article Title: DNL343 and disease progression in amyotrophic lateral sclerosis

Article References: DNL343 and disease progression in amyotrophic lateral sclerosis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ALS, DNL343, eIF2B, integrated stress response, randomized clinical trial, neurodegeneration, motor neurons, JAMA Network Open, drug development, protein synthesis, clinical trial failure, Denali Therapeutics